ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "prognostic factors"

  • Abstract Number: 0329 • ACR Convergence 2022

    Scoring Personalized Molecular Portraits Identify Systemic Lupus Erythematosus Subtypes and Predict Individualized Drug Responses, Symptomatology and Disease Progression

    Daniel Toro-Domínguez1, Manuel Martinez-Bueno1, Raúl López-Domínguez2, Jordi Martorell-Marugán1, Elena Carnero-Montoro1, Guillermo Barturen1, Daniel W. Goldman3, Michelle Petri3, Pedro Carmona-Sáez2 and Marta Alarcon-Riquelme1, 1Center for Genomics and Oncological Research (GENYO), Granada, Spain, 2University of Granada, Granada, Spain, 3Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD

    Background/Purpose: Systemic Lupus Erythematosus is a complex autoimmune disease that leads to important worsening of quality of life and mortality. Flares appear unpredictably during the…
  • Abstract Number: 1154 • ACR Convergence 2022

    Axial Spondyloarthritis: Profiling of MiRNAs in Peripheral Blood Mononuclear Cells

    Aneta Pekčcová1, Kristýna Bubová2, Monika Gregova3, Šárka Forejtová2, Jana Hořínková2, Markéta Hušáková2, Michal Tomcik4, Jindřiška Gatterová2, Jiří Vencovský5, Karel Pavelka6, Ladislav Šenolt5 and Jiří Baloun2, 1Institue of Rheumatology, Prague, Prague, Czech Republic, 2Institue of Rheumatology, Prague, Czech Republic, 3Institue of Rheumatology, Prague, 4Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 5Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 6Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic

    Background/Purpose: microRNAs (miRNAs) are small non-coding RNAs, which are essential for correct gene expression. The dysregulation in miRNA expression is accompanied by various diseases and…
  • Abstract Number: 2049 • ACR Convergence 2022

    ILD Associated with Primary Sjögren’s Syndrome Is Frequently Progressive

    Anna-Maria Hoffmann-Vold1, Håvard Fretheim1, Phoung Phoung Diep1, Karoline Lerang2, Birgir Gudbransson1, Helena Andersson1, Øyvind Midtvedt1, Torhild Garen1, Michael Durheim1, Trond Mogens Aaløkken1, Øyvind Palm1 and Øyvind Molberg2, 1Oslo University Hospital, Oslo, Norway, 2Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway

    Background/Purpose: Interstitial lung disease (ILD) in primary Sjögren's syndrome (pSS) has been reported to be present in 10-15% of patients, but ILD progression in pSS-ILD…
  • Abstract Number: 1228 • ACR Convergence 2021

    Predicting RA Remission with Subcutaneous Abatacept Treatment in the Real-world Setting

    Rieke Alten1, Christiane Rauch2, Bettina Bannert3, Sara Marsal4, Maya Buch5, Roberto Caporali6, Melanie Chartier7, Sean Connolly8, Hedley Griffiths9, Xavier Mariette10, Michael Nurmohamed11, Yusuf Patel12, Peter Peichl13, Raimon Sanmarti14, Yedid Elbez15 and Karissa Lozenski8, 1Schlosspark-Klinik University, Berlin, Germany, 2Bristol Myers Squibb, Munich, Germany, 3Universitätsspital Basel, Basel, Switzerland, 4Hospital Universitari Vall d’Hebron, Barcelona, Spain, 5University of Leeds, Leeds, United Kingdom, 6Policlinico S. Matteo University, Pavia, Italy, 7Bristol Myers Squibb, Rueil-Malmaison, France, 8Bristol Myers Squibb, Princeton, NJ, 9Barwon Rheumatology Service, Geelong, Australia, 10Université Paris-Saclay, AP-HP, Hospital Bicêtre, Paris, France, 11ARC Amsterdam University Hospitals – VU University Medical & Reade, Amsterdam, Netherlands, 12Hull Royal Infirmary, Hull, United Kingdom, 13Evangelical Hospital, Vienna, Austria, 14Hospital Clínic de Barcelona, Barcelona, Spain, 15Deepscover, Puteaux, France

    Background/Purpose: A treat-to-target approach for RA management is recommended, with the aim of achieving remission.1,2 The Abatacept SubCutaneOus in Routine clinical practicE (ASCORE; NCT02090556) study…
  • Abstract Number: 1356 • ACR Convergence 2021

    Effects of TNF-α versus Secukinumab on Active Ultrasound Confirmed Enthesitis in Psoriatic Arthritis

    Ashley Elliott1, Gary Wright2, Adrian Pendleton2 and Madeleine Rooney1, 1Centre for Experimental Medicine , School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, UK, Belfast, Northern Ireland, United Kingdom, 2Belfast Health and Social Care Trust, Belfast, Northern Ireland, United Kingdom

    Background/Purpose: Enthesitis is an important aspect of disease in PsA and its clinical assessment has problems in terms of sensitivity and overlap with alternative co-morbid…
  • Abstract Number: 1363 • ACR Convergence 2021

    Identification of PsA Phenotypes with Machine Learning Analytics Using Data from a Phase 3 Clinical Trial Program of Guselkumab in a Bio-naïve Population of Patients with PsA

    Pascal Richette1, Marijn Vis2, Sarah Ohrndorf3, William Tillett4, Marlies Neuhold5, Michel van Speybroeck6, Elke Theander7, Wim Noel8, May Shawi9, Alexa Kollmeier10 and Alen Zabotti11, 1Lariboisiere Hospital, Paris, France, 2Erasmus MC, Badhoevedorp, Netherlands, 3Charité University Medicine Berlin, Berlin, Germany, 4Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 5Janssen-Cilag, Zug, Switzerland, 6Janssen Pharmaceutica, Belgium, Belgium, 7Janssen Cilag, Lund, Sweden, 8Janssen Pharmaceutica, Vilvoorde, Belgium, 9Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, 10Janssen Research & Development, LLC, La Jolla, CA, 11University of Udine, Udine, Italy

    Background/Purpose: Psoriatic arthritis (PsA) is mainly described based on the individual domains or clinical components of the disease.1,2 The aim of this post hoc analysis…
  • Abstract Number: 1364 • ACR Convergence 2021

    Autologous Hematopoietic Stem Cell (HSC) Transplantation for Systemic Sclerosis, North American Registry: Updated Outcomes and the Impact of CD34+ HSC Enrichment

    George Georges1, Keith Sullivan2, Dinesh Khanna3, Matthew Mei4, Maureen Mayes5, Dan Furst6, Mark Wener7, Suzanne Kafaja8, Gwynn Long2, Vaishali Sanchorawala9, Kareem Jamani10, Attaphol Pawarode3, Ashish Masurekar11, Brian Lam12, Richard Nash13, Marcin Trojanowski9, Chitra Hosing14, Philip Clements15, Tanya Helms2, Bernadette McLaughlin16, Linda Griffith17, Kyle Hebert18, Mary Eapen18, Jan Storek10 and Harold Atkins11, 1Fred Hutchison Cancer Research Center and University of Washington, Seattle, WA, 2Duke University School of Medicine, Durham, NC, 3University of Michigan, Ann Arbor, MI, 4City of Hope Comprehensive Cancer Center, Duarte, CA, 5Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, 6University of California Los Angeles, Los Angeles, CA, 7University of Washington, Seattle, WA, 8University of California Los Angeles Division of Rheumatology, Los Angeles, CA, 9Boston University School of Medicine, Boston, MA, 10University of Calgary, Calgary, AB, Canada, 11Ottawa Hospital Research Institute, Ottawa, ON, Canada, 12University of Texas McGovern Medical School, Houston, TX, 13Colorado Blood Cancer Institute, Denver, CO, 14University of Texas MD Anderson Cancer Center, Houston, TX, 15University of California Los Angeles School of Medicine, Department of Rhemumatology, Los Angeles, CA, 16Fred Hutchison Cancer Research Center, Seattle, WA, 17Division of Allergy Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, 18Medical College of Wisconsin, Milwaukee, WI

    Background/Purpose: Autologous hematopoietic stem cell transplantation (AHSCT) is now established as a preferred standard of care treatment for patients with severe scleroderma with internal organ…
  • Abstract Number: 1390 • ACR Convergence 2021

    A 5% Increase in Interstitial Lung Disease at 1-Year Follow-up Is Associated with Long-Term ILD Progression in Systemic Sclerosis

    Alicia Hinze1, Shreyasee Amin1, Ashima Makol1, Robert Vassallo1, Cynthia Crowson2 and Brian Bartholmai1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Eyota, MN

    Background/Purpose: The clinical course of interstitial lung disease (ILD) in systemic sclerosis (SSc) is highly variable. Some patients experience a progressive decline in lung function…
  • Abstract Number: 1539 • ACR Convergence 2021

    High Disease Activity, as Assessed by RAPID3, Increases Risk of Hospitalization and Predicts Lower Chance of Recovery from COVID-19 in a Cohort of Tertiary Care Rheumatology Patients

    Matas Orentas1, Sonali Khandelwal2, Michael Grant2, Yanyu Zhang1, Najia Shakoor2 and Sobia Hassan1, 1RUMC, Chicago, IL, 2Rush University, Chicago, IL

    Background/Purpose: There is a need to understand which patients with rheumatologic diseases may be at highest risk for poor COVID-19 related outcomes so that both…
  • Abstract Number: 1630 • ACR Convergence 2021

    Multisystem Inflammatory Syndrome in Children: Clinical Characteristics and Predictors for Length of Hospitalization

    Lauren Covert1, Mara Becker2, Rebecca Sadun1 and Heather Van Mater1, 1Duke University, Durham, NC, 2Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, NC

    Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a recently defined post-infectious phenomena associated with coronavirus disease 2019 (COVID-19). We assessed the demographics, clinical characteristics,…
  • Abstract Number: 0014 • ACR Convergence 2021

    Low Baseline Expression of Pyruvate Kinase and Succinate Dehydrogenase Genes in the Peripheral Blood of Rheumatoid Arthritis Patients Treated with Tofacitinib Is Associated with Clinical Remission at the End of Follow-up

    Elena Tchetina1, Azamat Satybaldyev2, Galina Markova1 and Alexander Lila2, 1Nasonova Research Institute of Rheumatology, Moscow, Russia, 2V.A. Nasonova Reseach Institute of Rheumatology, Moscow, Russia

    Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease of unknown etiology, which is characterized by erosive arthritis and systemic inflammation. Tofacitinib (TFCN) is a Janus…
  • Abstract Number: 1775 • ACR Convergence 2021

    Isolated Axial versus Concomitant Peripheral Disease in Psoriatic Arthritis

    Timothy Kwok1, Mitchell Sutton2, Richard Cook3, Daniel Pereira4 and Dafna Gladman5, 1Toronto Western Hospital, University Health Network, University of Toronto, Toronto, ON, Canada, 2Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, 3Department of Statistics and Actuarial Sciences, University of Waterloo, Waterloo, ON, Canada, 4University Health Network, Toronto, ON, Canada, 5Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Isolated axial involvement exists in 2 to 5% of all psoriatic arthritis (PsA) patients. However, it is currently unknown whether patients with isolated axial…
  • Abstract Number: 0083 • ACR Convergence 2021

    Cardiac Valve Surgery Outcomes in the Antiphospholipid Syndrome

    Tali Eviatar1, Stanley Niznik2, Nancy Agmon-Levin2 and Daphna Paran3, 1Tel Aviv Sourasky Medical Center, Givataim, Israel, 2Sheba Medical Center, Ramat Gan, Israel, 3Tel Aviv Sourasky Medical Center-Ichilov Hospital, Even Yehuda, Israel

    Background/Purpose: Cardiac valve involvement in the APS is prevalent, necessitating valve surgery in about 5% of the patients. Data regarding valve surgery outcomes in APS…
  • Abstract Number: 1834 • ACR Convergence 2021

    To What Extent Do Clinical Features of PsA Predict Achievement of Minimal Disease Activity at Week 24: A Post Hoc Analysis of the Phase III Clinical Trial Program of Guselkumab in a Bio-naïve Patient Population

    Marijn Vis1, Pascal Richette2, Ramirez Julio3, Marlies Neuhold4, Robert Wapenaar5, Elke Theander6, Wim Noel7, May Shawi8, Alexa Kollmeier9 and William Tillett10, 1Erasmus MC, Badhoevedorp, Netherlands, 2Lariboisiere Hospital, Paris, France, 3Hospital Universitari Clinic, Barcelona, Spain, 4Janssen-Cilag, Zug, Switzerland, 5Janssen-Cilag BV, Breda, Netherlands, 6Janssen Cilag, Lund, Sweden, 7Janssen Pharmaceutica, Vilvoorde, Belgium, 8Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, 9Janssen Research & Development, LLC, La Jolla, CA, 10Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

    Background/Purpose: Guselkumab (GUS), a human monoclonal antibody targeting the interleukin-23p19-subunit, has demonstrated efficacy across joint and skin endpoints at Week 24 (W24) in the Phase…
  • Abstract Number: 0254 • ACR Convergence 2021

    Patient and Disease-Level Factors Associated with Sustained Cessation of Medication for Disease Remission in Systemic Juvenile Idiopathic Arthritis

    Elaine Flanagan1, Rosemary Peterson2, Susan Shenoi3, Helena Chang4, Kelly Wang4, Rebecca Trachtman4 and Karen Onel5, 1Emory/CHOA, Atlanta, GA, 2Dell Children's Medical Center, Austin, TX, 3Seattle Children's Hospital, Seattle, WA, 4Icahn School of Medicine at Mount Sinai, New York, NY, 5Hospital for Special Surgery, New York, NY

    Background/Purpose: The emergence of IL-1 and IL-6 inhibitors (biologics) for the treatment of systemic juvenile idiopathic arthritis (SJIA) has dramatically improved patient outcomes. With higher…
  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 21
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology